Sofosbuvir plus peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

April 25, 2015, European Association for the Study of the Liver

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks (71%, p <0.001).

"Sofosbuvir in combination with and with and without have never been directly compared before to determine sustained virologic response 12 weeks after treatment. This study highlights that with ribavirin and peginterferon should be considered for interferon-eligible GT-3 patients, particularly for those with and/or prior treatment failure," said Graham Foster, Professor of Hepatology, Queen Marys University of London, UK.

Of 592 patients randomised and treated, 92% had GT-3 HCV, 67% were male, 84% white, 53% treatment experienced, 62% had non-CC IL28B genotypes and 37% had cirrhosis.

The study also evaluated the safety and efficacy of SOF+PEG/RBV for 12 weeks vs SOF+RBV for 16 or 24 weeks in treatment-experienced genotype-2 (GT-2) HCV-infected patients with cirrhosis. GT-2 treatment-experienced patients with cirrhosis had high SVR12 rates in all treatment arms; 87% of those receiving SOF+RBV for 16 weeks, 100% of those receiving SOF+RBV for 24 weeks and 94% of those receiving SOF+PEG/RBV for 12 weeks.

"BOSON is a ground-breaking new study that provides information about how we can ensure the best outcomes for both GT-2 and GT-3 hepatitis C-infected patients. It has confirmed that 24 weeks is the optimal duration for a sofosbuvir and ribavirin combination in GT-3 patients, whilst also finding that sofosbuvir and ribavirin with peginterferon for 12 weeks resulted in the highest SVR12 rates observed to date in a Phase 3 study," said Professor Tom Hemming Karlsen, Scientific Committee Member, European Association for the Study of the Liver (EASL).

Explore further: Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C


Related Stories

Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C

April 24, 2015
A new study presented today at The International Liver Congress 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; ...

Combination therapy offers new hope for difficult-to-treat patients with chronic hepatitis C

April 23, 2015
Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high ...

All-oral, direct-acting antivirals show promise for hep C and HIV co-infected, cirrhotic patients

April 23, 2015
A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response ...

Daclatasvir-sofosbuvir combination highly effective and well tolerated in patients with hepatitis C

April 23, 2015
Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks ...

Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients

April 12, 2014
Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ...

Grazoprevir-elbasvir combo shows high cure rate for patients with chronic HCV

April 24, 2015
Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naïve patients with cirrhotic or non-cirrhotic ...

Recommended for you

Non-invasive malaria test wins Africa engineering prize

June 24, 2018
Languishing with fever and frustrated by delays in diagnosing his illness, Brian Gitta came up with a bright idea: a malaria test that would not need blood samples or specialized laboratory technicians.

Study reveals new therapeutic target for slowing the spread of flu virus

June 22, 2018
Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, Ph.D., ...

First ancient syphilis genomes decoded

June 21, 2018
An international research team, including scientists from the Max Planck Institute for the Science of Human History, the University of Tübingen, the National School of Anthropology and History in Mexico City, and the University ...

Rhesus macaque model offers route to study Zika brain pathology

June 21, 2018
Rhesus macaque monkeys infected in utero with Zika virus develop similar brain pathology to human infants, according to a report by researchers at the California National Primate Research Center and School of Veterinary Medicine ...

California Aedes mosquitoes capable of spreading Zika

June 21, 2018
Over the last five years, Zika virus has emerged as a significant global human health threat following outbreaks in South and Central America. Now, researchers reporting in PLOS Neglected Tropical Diseases have shown that ...

Breakthrough treatment for crippling jaw disease created

June 20, 2018
A first-ever tissue implant to safely treat a common jaw defect, known as temporomandibular joint dysfunction, has been successfully tested by UCI-led researchers in a large animal model, according to new findings.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.